Based on the change of the platelet reactivity in patients with diabetes, the clinical studies of potent P2Y12 inhibitor such as prasugrel [35] and ticagrelor [36] showed a favorable outcome following PCI in diabetic patients. Here, P2RY12 is linked to diabetes mellitus.